Monoclonal antibody | |
---|---|
Type | ? |
Target | α-Synuclein |
Clinical data | |
Other names | BIIB054; BIIB-054; NI-202; NI202 |
Identifiers | |
CAS Number | |
DrugBank | |
UNII |
Cinpanemab (INN , USAN ; developmental code names BIIB054, NI-202) is an anti-α-synuclein drug acting as a monoclonal antibody against α-synuclein which was under development for the treatment of Parkinson's disease.[1][2] It showed no significant influence on disease progression in a 52-week phase 2 clinical trial.[2] The drug reached phase 2 clinical trials but was discontinued in 2021 due its lack of effectiveness.[1][3][2] It was under development by Biogen.[1]